Top FIFA players initiate "11 Against Ebola" campaign

This is the primary emergency health campaign of its kind enforced by FIFA and CAF and is galvanized by the dedication of medical personnel at the front line of the fight against Ebola hemorrhagic fever.

Neymar Jr. (Barcelona/Brazil)The campaign is meant to supply a assuasive, positive message to affected communities with straightforward and clear info which will facilitate to combat the unfold of the Ebola virus.

Through the facility and recognition of soccer, the eleven Against Ebola hemorrhagic fever campaign seeks to succeed in as wide associate audience as attainable within the most affected regions and globally by connexion forces with high international soccer players, the planet Bank, FIFA and CAF member associations, native organizations and also the media.

The “11 Against Ebola” campaign, options World Player of the Year, Real capital of Spain’s Cristiano Ronaldo, Barcelona’s Neymar Jr, Chelsea’s Didier Drogba and Bayern Muenchen’s Philipp Lahm. alternative players concerned at the beginning of the campaign square measure Gareth Bale (Real Madrid/Wales), Raphaël Varane (Real Madrid/France), Neymar Jr. (Barcelona/Brazil), Gerard Piqué (Barcelona/Spain), Xavi (Barcelona/Spain), Jérôme Boateng (Bayern Munich/Germany), John cult Mikel (Chelsea/Nigeria), Saint George Davies (Sierra Leone) and Bayern Muenchen coach spirit Guardiola.

Ebola Virus Complete Fact Sheet

Ebola virusEbola virus disease (EVD), better known in past as viral hemorrhagic fever, could be a severe, typically fatal human disease. The Ebola virus causes an acute, serious illness, which is commonly fatal if untreated. Ebola virus disease (EVD) first appeared in 1976 in a pair of coinciding outbreaks, one in Nzara, Sudan, and the other in Yambuku, Democratic Republic of Congo. The latter occurred in an exceedingly village close to the Ebola river, which it takes its name.

Pharmacology Refresh Cards: Noradrenaline - Norepinephrine

Noradrenaline  -  norepinephrine
Drug name
Sympathomimetic   (Vasopressor)
Stimulates alpha-receptors in arterial and venous beds and beta1 receptors of heart, resulting in peripheral vasoconstriction and stimulation of heart rate and contractility. Coronary vasodilation occurs secondary to enhanced myocardial contractility.
Mechanism of action

Cont. infusion
0.01–0.4 µg/kg/min IV infusion via a central vein         
Septic shock ,with low SVR
Severe hypertension may occur if noradrenaline is given to patients taking tricyclic antidepressants since tricyclics block the uptake of noradrenaline into nerve endings.
Drug interaction
Myocardial ischaemia
peripheral ischaemia
Side effects

Hypovolaemic shock
Acute myocardial ischaemia or MI
Contraindication & precaution
Pregnancy: Category D
Special populations

Norepinephrine may lose potency in normal saline solution
Administer in D5W or 5% dextrose in saline
If extravasation occurs, infiltration with phentolamine
Administration notes
4mg/4ml amp
Availability in pharmacy

Other notes

Calcium Carbonate versus Calcium Acetate as Phosphate binder

Phosphate binder
Ph D: Neven Mohamed
For many years, calcium-containing phosphate binders (calcium acetate and calcium carbonate) were considered the best choice in the treatment of hyperphosphatemia, due to they are effective, possessed only moderate side-effects and suppressed parathormone levels with the intention of counteracting progression of secondary hyperparathyroidism. In two head-to-head observational studies (CARE, ARNOS), calcium-containing binders showed signals of clinical superiority versus the comparator sevelamer-HCl.[1.2] 

Nevertheless, calcium may be absorbed significantly, which may result in a positive calcium balance and actively contribute progressive cardiovascular and soft-tissue calcification in patients at risk.[3]

15 Facts about HARVONI the recent Hepatitis C from Gilead

HARVONI is a combination of ledipasvir (90mg), a (HCV) NS5A inhibitor, and sofosbuvir (400mg), an HCV nucleotide analog NS5B polymerase inhibitor. HARVONI was approved by FDA on 10 October 2014, as first Hepatitis C drug combination, that used alone without need to ribavirin or peginterferon alfa, as in case of SOVALDI.

Here are 15 facts about the new drug, that pharmacist needs to know to help him in dealing with the Hepatitis C newest treatment.